Videos

Jeffrey Schneider, MD, and Marc Braunstein, MD, PhD, spoke about their recent article published in the journal ONCOLOGY® regarding the management of patients with cancer during the COVID-19 pandemic.

The leukemia expert spoke about the importance of genetic testing for patients with acute myeloid leukemia and other important considerations for this patient population throughout the pandemic.

Venetoclax was granted approval in combination with azacitidine, decitabine, or low dose cytarabine earlier this month for adults 75 years or older with newly diagnosed acute myeloid leukemia or those who have comorbidities precluding intensive induction chemotherapy.

The expert in breast imaging spoke about the latest in breast imaging and the new technologies that are helping to advance the field.

The expert in breast imaging spoke about the use of the technology, and why it is more effective than traditional mammograms.

New research from NCI-MATCH support the feasibility and efficiency of using next-generation sequencing (NGS) to triage patients to investigational therapy, given that a sufficiently large pool of agents is provided.

The breast cancer expert discussed the changes he has made in treating this patient population as a result of the COVID-19 pandemic.

New research reported that guidelines to reduce the number of opioids prescribed to patients following surgery may be missing a small group of patients that need a greater level of pain control.

Among accredited US cancer centers, hospitals which serve primarily minority patients were found to be as likely as other hospitals to offer the standard of surgical care for early-stage breast cancer.

Research suggested that limited English-language proficiency is a risk factor for getting potentially lifesaving screening mammograms less often.

Researchers found that patients who participated in virtual follow-up visits benefitted by spending less time waiting at and traveling to the clinic for in-person appointments.

Moss indicated that “we need interventions in these communities to change cancer-causing behaviors, to make cancer screening more accessible, to improve treatment, and to promote quality of life and survivorship.”

The expert from the Otto J. Ruesch Center for the Cure of Gastrointestinal Cancers discussed precision medicine with regard to cancer care, as well as the need to make such care more accessible for the global community.

The findings from this study are intended to inform the Curriculum for Oncologists on LGBTQ+ populations to Optimize Relevance and Skills (COLORS) Training Program.

According to researchers, a “better understanding of the heterogeneity of mCRC, including primary tumor location, microsatellite instability (MSI) status, and other clinically actionable tumor mutations, is reshaping the therapeutic landscape.”

According to researchers, these early data support the rationale for further evaluation of immune-checkpoint inhibitor-based combinations in patients with metastatic castration resistant prostate cancer.

The liquid biopsy was approved by the FDA for comprehensive genomic profiling in patients with any solid malignant neoplasm.

The cancer specialist from Cedars-Sinai spoke about the observed increase of colorectal cancer in younger individuals, as well as the significantly higher incidence and death rates in black people.

New guidelines published by the American Society for Clinical Oncology (ASCO) on the use of PARP inhibitors in the management of ovarian cancer included the myChoice CDx as the sole companion diagnostic to be used in this space.

The medical oncologist spoke about the need to make next-generation sequencing available to all patients with gastrointestinal cancer.

The liquid biopsy test is approved to identify patients who may benefit from treatment with specific FDA-approved targeted therapies.

The model was found to be superior to the United States Preventive Services Task Force (USPSTF) criteria at identifying African American ever-smokers for lung cancer screening.